Evaluation of the Effect of Two Types of Fluid in the Recovery From Anaesthesia. Voluven 6% v Hartmanns

Study Overview
=================
Brief Summary
-----------------
Avoiding nausea and vomiting is one of the most important for patient comfort and satisfaction, and preventing unplanned overnight stays in hospital following surgery. Studies have shown that increased amounts of intravenous fluid during surgery prevent nausea and vomiting after operations. This effect lasted for up to 48 hours after the surgery. Other unpleasant side effects of dehydration that delay recovery including headaches and dizziness can be prevented with fluid treatment during the operation. It is unclear if this effect happens with all types of fluid. The investigators propose to examine the effect of 2 types of intravenous fluids on recovery from anaesthesia. Each group will be given a different fluid while using our usual anaesthetic technique. The investigators will ask questions about nausea and vomiting after surgery (primary outcomes), and other factors relating to patient comfort such as headache and dizziness (secondary outcomes)

Detailed Description
-----------------
Treatment of postoperative nausea and vomiting (PONV) is extremely important for patient comfort and satisfaction after surgery.1 There has been a recent change in emphasis from inpatient to day care surgery and anaesthesia with attendant increased interest in the problem of PONV. The incidence of PONV following day case gynaecologic surgery is 40% to 90%.2,3 Postoperative nausea and vomiting has the potential to cause delays in meeting discharge criteria both from the recovery room to ward, and from the day ward to home. On rare occasions, it may lead to unanticipated overnight hospital admission which leads to an increased emotional cost to the patient and economic cost to the healthcare provider. The efficacy of routine use of prophylactic antiemetics remains controversial.4 Pharmacologic prophylaxis has limited effect and increases the risk of adverse drug effects for the patient in addition to increasing overall cost of care.5,6 Studies suggest that increased crystalloid infusion for day case gynaecologic procedures in healthy patients reduces the incidence of nausea, vomiting and antiemetic use.7,8 The suggested mechanism is an improvement in gastrointestinal mucosal perfusion that mitigates the both the deleterious effects of preoperative fasting and consequent dehydration,9 and those of raised intra-abdominal pressure and surgical manipulation of bowel during laparoscopic procedures. However, excessive fluid administration in major surgery has been shown to have a negative effect on postoperative gastrointestinal function (causing an increased incidence of postoperative ileus) due to bowel oedema.10 It has been demonstrated that colloid causes less bowel oedema than equivalent volumes of crystalloid.11 Moretti et al showed that intraoperative colloid administration reduces PONV and improves the quality of postoperative recovery versus crystalloid solutions.¹² Clearly, there is an optimum perioperative fluid balance to reduce PONV without the risk of additional gastrointestinal side effects. An arbitrary perioperative fluid load measured in ml.kg-1 does not take account of the individual fasting period and resultant preoperative fluid deficit for each patient, which can vary substantially depending on early or late (morning or afternoon) operating time. We propose to prospectively examine the effect of intravenous fluids on PONV in a double-blind study, utilizing a standardised anaesthetic technique as normally carried out in this hospital. We hypothesise that replacement of preoperative fluid deficit with colloid will reduce the incidence of PONV versus crystalloid solution. We further propose to examine secondary outcomes relating to patient wellbeing such as headache and dizziness which are symptoms of dehydration. Healthy patients should not experience any cardiorespiratory effects associated with administration of intravenous fluids to correct dehydration due to preoperative fasting. There may however be subclinical effects which can be detected by sensitive pulmonary function testing. Patients will be asked to perform a simple bedside lung function test before surgery and 2 hours after surgery. This will be done with a portable spirometer (Micromedical Micro Lab Spirometer), which is used routinely in our anaesthesia preoperative assessment clinic to evaluate lung function. Forced expiratory volume in the first second (litre) (FEV1), forced vital capacity (litre) (FVC) and peak flow rates (l/min) will be measured at a 45 degree position of recumbency. The best of three attempts will be chosen for further analysis as recommended by the British Thoracic Society. Methods LOCATION · Rotunda Hospital, operating theatres, recovery room and gynaecology ward STUDY DESIGN · Prospective, randomised, double-blind INCLUSION CRITERIA ASA I-II female patients Age 18-45 years Undergoing minor elective gynaecological surgery (elective laparoscopy) EXCLUSION CRITERIA Age <18 or > 45 Cardio-respiratory disease Excessive intraoperative blood loss Obesity: BMI >30 Relevant drug allergy to medication used in the protocol INFORMED WRITTEN CONSENT · Informed written consent will be obtained from all patients (see appendix 1) RANDOMISATION · Patient group will be determined by randomisation with a computer program random number generator GROUPS Patients will be allocated to one of two groups according to randomisation Group 1 will receive 1.5 ml.kg.hr-1 of fasting time of intravenous Hartmann's solution perioperatively (Crystalloid solution) Group 2 will receive 1.5 ml.kg.hr-1 of fasting time of intravenous Voluven® (6% Hydroxy Ethyl Starch) solution perioperatively (Colloid solution) BLINDING All fluid administration will be completed in theatre Neither the patient or the investigator will be aware of group assignment ANAESTHETIC TECHNIQUE The anaesthetic technique will be standardised as follows: Intravenous access will be obtained after local anaesthetic infiltration of the skin. Once the fluid has been started all patients will undergo a standardised induction of anaesthesia, consisting of Fentanyl 1.5 mcg.kg-1, Propofol 2-3 mg.kg-1 and Atracurium 0.35 mg.kg-1 to facilitate airway control. All patients will be mechanically ventilated via a laryngeal mask airway LMA Supreme™ to maintain isocapnia with tidal volume (Vt) 4-6 ml.kg-1, maximum airway pressure (P max) 30 cm H2O and a positive end expiratory pressure (PEEP) of 5 cm H2O. Anaesthesia will be maintained with Sevoflurane 1-3% in a mixture of O2 and air to achieve a FiO2 of 0.5. Muscle relaxation will be antagonised with Neostigmine 2.5 mg and Glycopyrrolate 0.5 mg at the end of surgery. Before discontinuation of anaesthesia, each patient will receive rectal Diclofenac 100mg and 1000mg Paracetamol i.v. Postoperative care will also be standardised. Patients complaining of pain will be given 25 mcg of Fentanyl intravenously as required (in PACU), Pethidine 50mg intramuscularly or simple oral analgesics (Paracetamol/Codeine 500-1000mg/8-16mg) every 6 hours in the ward area. Rescue antiemetics in the form of boluses of Ondansetron 4mg intravenously (to a maximum total dose of 16mg) and Cyclizine 50mg intramuscularly every 8 hours can be given. Patients will be prescribed oral Paracetamol/Codeine 500-1000mg/8-16mg every 6 hours and Diclofenac 50mg every 8 hours to take at home if required. MEASUREMENTS (assessed by a single data collector @ 30 mins, 2 hours, 24 hours and 48 hours postoperatively) Nausea: using a standard verbal analogue scale (VAS 0 - 10) Vomiting: Y/N, number of episodes Rescue antiemetics administered Dizziness: Y/N Sore throat: Y/N Headache: Y/N Wellbeing: assessment of general wellbeing on a scale from 0 - 10 Pulmonary Function Tests TREATMENT OF DATA The data will be collected by a single investigator at the specified time points and documented on a patient data collection sheet (see appendix 2). Once data collection is complete, all data of the patient sheets will be transferred onto a spreadsheet and anonymised. USE OF DATA The data will be presented at a national or international meeting and in peer-reviewed medical journals. STORAGE OF DATA All data will be stored for five years and only Dr. Conan McCaul and Dr. Ivan Hayes will have access to them. STATISTICAL PROCEDURES Statistics will be performed using a standard statistical program (Sigma Stat, Jandel Scientific). Demographic data will be analysed using Student's t-test or Fisher's exact test as appropriate. Repeated measures ( VAS scores) will be analysed by repeated measures analysis of variance with further paired comparisons at each time interval performed using the t-test, with corrections for multiple comparisons where appropriate. Categorical data will be analysed using χ² analysis or the Fisher's exact test where applicable. Normally distributed data will be presented as means +/-SEM, non-normally distributed data will be presented as medians +/- quartiles (interquartile range), and categorical data will be presented as raw data and as frequencies. SAMPLE SIZE Postoperative nausea and vomiting incidence from day case laparoscopic gynaecologic procedures (primary outcome) both with and without single agent antiemetic prophylaxis varies from 40 -90%.2,3,7 To detect a clinically significant difference of 25% reduction in mean nausea scores based on a PONV incidence of 40% without antiemetic prophylaxis, we calculate a sample size of 60 patients per group (a = 0.05, β = 0.2).

Official Title
-----------------
Evaluation of the Effects of Two Types of Fluid in the Recovery From Anaesthesia.

Conditions
-----------------
Postoperative Nausea and Vomiting

Intervention / Treatment
-----------------
* Other: fluid administration


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: American Society of Anaesthesiology classification 1 & 2 Minor laparoscopic gynaecological surgery Age 18-45 Exclusion Criteria: Age <18 or > 45 Cardio-respiratory disease Obesity: BMI >30 Relevant drug allergy to medication used in the protocol

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Hartmanns<br>These patients will receive Hartmanns during anaesthesia | Other: fluid administration<br>* 1.5mls/kg/hr fasting<br>|
| Active Comparator: Voluven 6%<br> | Other: fluid administration<br>* 1.5mls/kg/hr fasting<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of nausea and vomiting |  | 120 mins | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of Headache |  | 30 mins | 
| Incidence of headache |  | 120 mins | 
| Incidence of headache |  | 24 hours | 
| Incidence of headache |  | 48 hours | 
| Incidence of nausea and vomiting |  | 30 mins | 
| Incidence of nausea and vomiting |  | 24 hours | 
| Incidence of nausea and vomiting |  | 48 hours | 
| Incidence of sore throat |  | 30 mins | 
| Incidence of sore throat |  | 120mins | 
| Incidence of sore throat |  | 24 hours | 
| Incidence of sore throat |  | 48 hours | 
| Incidence of dizzyness |  | 30 mins | 
| Incidence of dizzyness |  | 120 mins | 
| Incidence of dizzyness |  | 24 hours | 
| Incidence of dizzyness |  | 48 hours | 
| Verbal analogue scale of general wellbeing |  | 30 mins | 
| Verbal analogue scale of general wellbeing |  | 120 mins | 
| Verbal analogue scale of general wellbeing |  | 24 hours | 
| Verbal analogue scale of general wellbeing |  | 48 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Perioperative intravenous fluids